Let's move, with Hymovis!

We are pleased to announce the release of our new www.hymovis.net website, designed with a…

Global viscosupplementation market is anticipated to increase to over $2.64 billion by 2021

“Fidia Farmaceutici has invested in research and development of hyaluronic acid-based products for more than 70 years. Today, Fidia is growing its product portfolio with new, innovative solutions to meet challenges in the field of osteoarthritis using science, our legacy and our drive.”

PARSIPPANY, N.J.--(BUSINESS WIRE)--Fidia Farmaceutici S.p.A., a world leader in the research,…

Management of sleep disorders may result in significant improvement of general health. The first step is talk to the primary care provider.

Social media use is rapidly increasing, as well as daytime and bedtime use of computers, including…

The Company is finalizing the acquisition of Italian Sooft/Oox Group

As announced at the end of 2016, Fidia has finalized the first step to the successful acquisition of…

An update from Fidia Farmaceutici

Further to previous communications, regarding the development of a hair loss remedy initiated a few…


Find out more about Fidia’s product portfolio:

Go to the website

Key Business Areas

Fidia operates in numerous therapeutic areas, providing specific, innovative treatments for commonly occurring pathologies with major socio-economic impact, namely:

- joint care
- ophthalmology
- active wound care
- neuroscience
- aesthetic medicine